Literature summary for 3.4.14.5 extracted from

Raz, I.; Hanefeld, M.; Xu, L.; Caria, C.; Williams-Herman, D.; Khatami, H.; Khatami, H.
Efficacy and safety of the dipeptidyl peptidase-4 inhibitor sitagliptin as monotherapy in patients with type 2 diabetes mellitus (2006), Diabetologia, 49, 2564-2571.

Search for more literature for 3.4.14.5

Application

Application	Comment	Organism
medicine	sitagliptin significantly improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus who have inadequate glycaemic control on exercise and diet	Homo sapiens

Inhibitors

Inhibitors	Comment	Organism	Structure
sitagliptin	sitagliptin significantly improves glycaemic control and is well tolerated in patients with type 2 diabetes mellitus who have inadequate glycaemic control on exercise and diet	Homo sapiens

Organism

Organism	UniProt	Comment	Textmining
Homo sapiens	-	patients with type 2 diabetes mellitus	-

Use of this online version of BRENDA is free under the CC BY 4.0 license. See terms of use for full details.

Release 2023.1 (January 2023)